HPV detection methods and genotyping techniques in screening for cervical cancer.

Human papillomaviruses (HPV), double-stranded DNA viruses, are causing many mucocutaneous diseases, benign or malignant, ranging from common warts to malignancies involving the upper aerodigestive tract and the anogenital sphere. The diagnosis of HPV infection is based primarily on the viral genome detection by molecular biological methods, given the difficulty in routine cultivation of these viruses. The current trend in screening against cervical cancer is to improve the sensitivity of screening with new methods and to propose new algorithms for diagnostic and therapeutic decisions. The development of liquid-based cytology facilitates the cytologic diagnosis and molecular assays from the same sample. There are two main types of HPV detection methods used on uterine cervical samples: signal amplification methods (hybridization techniques in liquid phase) and target amplification methods (the techniques of gene amplification or Polymerase Chain Reaction [PCR]). Genotyping techniques are also developed: they are based on an amplification technique followed by hybridization with probe specific types. In addition to the detection, genotyping techniques allow quantitative detection of viral DNA of HPV genotype and so monitor changes in viral load over time. Another approach relies on the detection of messenger RNA (mRNA) of HPV proteins E6 and E7 oncogenes, which would appear to be a relevant marker to identify and monitor women at risk of progression to a precancerous lesion or cervical cancer.

[1]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[2]  Â. Pista,et al.  Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test , 2011, Journal of medical virology.

[3]  I. Kristiansen,et al.  HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. , 2011, Gynecologic oncology.

[4]  M. Rodríguez-Iglesias,et al.  Performance of the New INNO-LiPA HPV Extra to Genotype Human Papillomavirus in Cervical Cell Specimens , 2011, Acta Cytologica.

[5]  G. Wolf,et al.  Human papillomavirus status in head and neck cancer , 2010, Cancer.

[6]  A. Malpica,et al.  Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. , 2011, Gynecologic oncology.

[7]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[8]  J. Cuzick,et al.  Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study , 2012, Journal of Clinical Microbiology.

[9]  N. Muñoz,et al.  HPV in the etiology of human cancer , 2006 .

[10]  W. Quint,et al.  Differences in human papillomavirus type distribution in high‐grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe , 2013, International journal of cancer.

[11]  I. Nazarenko,et al.  An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  C. Wheeler,et al.  A Study of Amplicor Human Papillomavirus DNA Detection in the Atypical Squamous Cells of Undetermined Significance–Low-Grade Squamous Intraepithelial Lesion Triage Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[13]  C. Wheeler,et al.  A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study (Cancer Epidemiology Biomarkers and Prevention (2009) 18, 1, (1341-9)) , 2009 .

[14]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. , 2012, American journal of clinical pathology.

[15]  O. G. Wong,et al.  Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  V. Costes,et al.  Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high‐risk human papillomaviruses in cervical and anal scrapes , 2011, Journal of medical virology.

[17]  Xavier Castellsagué,et al.  Chapter 1: HPV in the etiology of human cancer. , 2006, Vaccine.

[18]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 1995. , 2002, European journal of cancer.

[20]  K. Murphy,et al.  Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. , 2011, The Journal of molecular diagnostics : JMD.

[21]  J. Charlot,et al.  Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study , 2008, International journal of cancer.

[22]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.